ArticleObesity surgery2026
Metabolic Outcomes of Laparoscopic Sleeve Gastrectomy: Short and Mid-Term Effects on Type 2 Diabetes and Hypertension in Patients with Obesity.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLaparoscopic sleeve gastrectomy (LSG) has become a frequently employed primary bariatric procedure in recent years. Our objective was to evaluate the short- and mid-term outcomes of LSG with regard to weight reduction and its impact on associated comorbidities, particularly hypertension (HTN) and type 2 diabetes mellitus (T2DM). MATERIALS AND
methods86 patients who underwent LSG between June 2015 and December 2022 and whose postoperative 6-month, 1-year, and 3-year follow-up records were available were included in this retro-prospective study. Preoperative height/weight values, comorbidities, drugs used for HTN and/or T2DM, and changes in postoperative 6-month, 1-year, 3-year, and 5-year data were collected.
resultscompared to preoperative data, decrease in Body Mass Index (BMI) was statistically significant. Improvement in hypertension was seen in 46.6% of subjects and resolution in 53.4% of study subjects. Resolution in Diabetes was seen in 71% of subjects and improvement in 29% of study subjects.
conclusionLaparoscopic sleeve gastrectomy (LSG), when used as a primary surgical treatment for morbid obesity, is a highly effective and reliable procedure with low morbidity and mortality rates. Furthermore, it results in significant regression of associated comorbidities, such as hypertension and type 2 diabetes mellitus.
Indexed as
Identifiers
41606352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.